相关实验视频
Updated: Jul 19, 2025

10:40
Author Spotlight: Insight Into Advances in Prion Diseases Research
Published on: August 11, 2023
507
炎症性微质中的代谢重编程表明,在阿尔茨海默病中向炎症的潜在方法是阿尔茨海默病
Moris Sangineto1, Martina Ciarnelli1, Tommaso Cassano2
1C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Redox biology
|August 16, 2023
概括
准微质细胞代谢可以预防阿尔茨海默病. 用二甲基酸 (DMM) 抑制糖酸脱酶 (SDH) 减少炎症并改变微质能量产生,为AD提供了潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 代谢过程中的代谢.
背景情况:
- 微质细胞的激活是阿尔茨海默病 (AD) 发病的核心,驱动神经炎症.
- 早期阿尔茨海默病的微质前炎性反应的代谢基础仍然不清楚.
- 准微质新陈代谢是预防AD的未经探索的治疗途径.
研究的目的:
- 为了阐明微质在炎症激活时的代谢重编程.
- 研究酸脱酶 (SDH) 在微质生物能学和炎症中的作用.
- 评估SDH抑制在阿尔茨海默氏病模型中的治疗潜力.
主要方法:
- 脂聚糖 (LPS) 暴露诱导微质激活.
- 评估细胞呼吸,糖解和反应性氧物种的产生.
- 使用二甲基酸盐 (DMM) 抑制SDH.
- 对低氧诱导因子1α (HIF-1α) 信号的分析.
- 在体内对3xTg-AD小鼠的研究和对5xFAD小鼠公开RNA测序数据的分析.
主要成果:
- 通过LPS激活的微质体表现出增加的葡萄糖分解和线粒体呼吸,反应性氧物种的产生增加.
- 治疗DMM调节微质代谢,减少炎症和改善线粒体功能.
- 通过DMM抑制SDH抑制HIF-1α激活,从而降低糖解和促炎性细胞因子的产生.
- 在3xTg-AD小鼠中,DMM的使用消除了脑炎症,并使微质代谢概况正常化.
- 转录基因分析证实了AD小鼠模型中的微质中改变的电子运输链 (ETC) 基因表达.
结论:
- 收费类受体4 (TLR4) 激活通过代谢变化诱导亲炎性微质表型.
- 酸脱酶 (SDH) 在调解这些LPS诱导的代谢转变和炎症反应方面发挥着关键作用.
- 准SDH是一种有前途的治疗策略,可以缓解神经炎症,并可能预防阿尔茨海默病的发病.
相关概念视频
Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215
Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521

